Drug intelligence / Profile preview

Erb-eVax

Development stage: Preclinical
Lead developer: EvviVax
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

Erb-eVax is a therapeutic DNA cancer vaccine being developed by EvviVax for the treatment of HER2/neu-positive canine tumors, leveraging a plasmid or linear DNA platform encoding the HER2/neu oncogene to induce robust cellular and humoral antitumor immune responses.[1][4][7][9] As a veterinary immunotherapy, it is designed to stimulate killer T cells, antibody production, and innate immunity against the HER2/neu-expressing tumor cells, with the goal of stabilizing or reducing tumor progression and potentially serving as a bridge to analogous approaches in human oncology.[1][3][4][5][9]

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on Erb-eVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erb-eVax.

Explore the full profile